Vice President and Global Head, Medical Device and Diagnostics Research, ICON Plc
Vicki Anastasi provides leadership to create and foster priority relationships in the medical device and diagnostic marketplace, developing customized programs to meet medical device client needs. She has over 25 years of experience in the medical device industry, with over 15 years specifically focused on global medical device strategic consulting.
EY Americas Medtech Leader
John Babitt is the EY MedTech leader for the Americas and is also the Life Sciences Leader for Financial and Accounting Transaction Advisory. John has over 20 years of experience, all in the healthcare industry, and originally joined E&Y in 1995. John’s corporate clients include but not limited to: Medtronic, Johnson & Johnson (including DePuy), Fresenius, GE Healthcare and Bayer, and significant PE clients including, Apax, Warburg Pincus, Avista Capital, Linden and Altaris.
Dr. Binur is a managing partner of Orchestra and has over 29 years of venture capital experience in the United States, Europe and Israel. He is co-founder of Accelerated Technologies, Inc. and served as its Chairman of the Board since its inception. He was founding Managing Partner of Medica and while there helped raise its first two venture funds and is a pioneer in the field of interventional pulmonology.
Principal, Panakes Partners
Barbara Castellano is the Principal of Panakes Partners. She is the former CEO of Techwald, as well as the former Director of Clinical Affairs, Certifications and Registrations of Quality Assurance CID SpA, and the former Director of Business Development of Heart Valves BU at Sorin.
Founder & CEO, MedTecX
Lifei Cheng is the Founder & CEO of MedTecX, a global medtech accelerator based in China, which strives to improve healthcare with patient needs first, by breaking down boundaries and accelerating global innovation.
Vice President Corporate Development, Medtronic
Chris Cleary is Vice President of Corporate Development for Medtronic. During 2014, Chris led the corporate development efforts for Medtronic’s $43B acquisition of Covidien. Since then, Medtronic has acquired over 30 businesses for more than $3 billion, and made more than 20 investments in companies and funds in excess of $170 million. Prior to 2014, Chris was CEO of Alesia Capital Services, and worked at GE Capital from 1995 to 2011, leading M&A teams that closed acquisitions worth $60 billion of financial assets across more than 200 transactions.
VP, Medical Devices & Director, Center for Device Innovation at the Texas Medical Center, Johnson & Johnson
Dr. William E. “Billy” Cohn is the Vice President for Johnson & Johnson Medical Devices Companies and the Executive Director of the new Center for Device Innovation at the Texas Medical Center in Houston. Dr. Cohn has a passion for medical device development and has more than 90 US patents granted or pending for his medical innovations that have provided the core technology for six venture-backed medical start-ups.
Investment Manager, European Investment Fund
Nick Dunster is an Investment Manager at European Investment Fund (EIF). EIF’s central mission is to support smart, sustainable and inclusive growth for SMEs in Europe's. We enhance SMEs' and small mid-caps access to finance by developing and offering equity and guarantee financial products to selected intermediaries across Europe, specifically targeting this segment.
MD, Partner, Sante Ventures
James joined Santé Ventures in 2010. Previously, James served in the Air Force and was the medical director and Vice-Chair of Emergency Medicine at Wilford Hall Medical Center, an academic level-one trauma center in San Antonio. He completed two tours in Iraq as a critical care transport team chief and as the emergency department commander. He separated honorably as a Major in 2008. James received his MBA from the University of Texas McCombs School Of Business, his MD from Harvard Medical School, and a BS in bioengineering, Summa Cum Laude, from the University of Michigan. He is board certified in emergency medicine and completed his residency at Massachusetts General Hospital and Brigham and Women’s Hospital.
Managing Director, JDRF T1D Fund
Katie Ellias joined the T1D Fund in July 2018 as a Managing Director from Endeavour Vision, a Geneva-based growth stage venture fund, where she focused on medical devices and digital health as Senior Investment Director. She was previously Principal at Sofinnova Partners, Paris, a leading early stage life sciences fund, investing in medical technologies. She served as Board Observer for ReCor Medical (sold to Otsuka Holdings), CorWave, Shockwave Medical, RefleXion Medical, Pixium Vision (PIX.PA), and MD Start, a medical device accelerator.
Partner, Gilde Healthcare Partners
Arthur Franken joined Gilde in 2001. He is focusing on venture and growth capital investments in the biopharm, medtech, diagnostics and digital health sectors. He represents Gilde on the boards of Breath Therapeutics, Calypso, Levicept, Moximed and Symphogen and served as a board member for FlowCardia, MTM Laboratories, ProQR Therapeutics and STAT-Dx until the trade sales or IPO. Prior to joining Gilde he was active in cardiovascular research at the Leiden/Amsterdam Center for Drug Research and TNO. He holds a master’s degree in Biopharmaceutical Sciences from Leiden University, the Netherlands.
Vice President, Lightstone Ventures
Caroline is Vice President at Lightstone Ventures (LSV), where she evaluates new investment opportunities in the biopharmaceutical and medical device sectors out of the firm’s Dublin office.
Prior to joining Lightstone, Caroline held the position of commercial and clinical lead on a number of early stage medical device projects and is director and founder of a start up in the healthcare IT space. Caroline has more than 10 years’ experience in the pharmaceutical industry where she held a variety of operational roles in regulatory affairs, product management, marketing and strategic business development in the oncology space. More recently Caroline held a senior management position as head of market access & reimbursement for Bayer Ltd. Ireland where she was responsible for health technology assessment applications and reimbursement negotiations with the national health services for novel drugs in the cardiovascular, oncological and hormonal therapy space.
Managing Partner & Founder, Innogest
Claudio Giuliano is a player in the venture capital industry since year 2000. Claudio co-founded in 2007 Innogest Capital, a Venture Capital firm with about € 200 Mln under management, and a partner in the Healthcare and Cardiovascular practice at Innogest. Prior to Innogest, Claudio was Associate Director at The Carlyle Group (London), Strategy consultant at Bain & Co (Italy), and Supply Chain Manager at Hewlett-Packard (California and France).
Director, Sales & Marketing, Surgical Endoscopy Group, Olympus
Townsend Goddard is currently leading a commercial organization across the EMEA region delivering above market growth in five surgical business units. Additionally, he is the executive sponsor for Olympus’ business development efforts in the region. Prior to joining Olympus, he held international leadership positions at both Covidien and Stryker.
Director of Health Investment, Pangaea Ventures
Janelle brings experience working in healthcare both in strategic and operations consulting and private investments for over eight years. Janelle has spent most of her career at GE Healthcare, based in both North America and Europe. She worked with both private and public health organizations and launched a startup that became a joint venture between GE and Microsoft. She brings her experience as an Associate with a leading Canadian private equity firm and most recently with a Vancouver-based Venture Capital firm investing in health technologies.
Managing Director, Global Head of Medtech, Locust Walk
Hunt Henrie joined Locust Walk as a Managing Director in 2017, and has spent the last 15 years at Ferghana Partners where he started and led the Medical Technology and Financing activities. Hunt brings to Locust Walk over 30 years of broad-based global financial, investment banking, private equity and corporate operating experience, of which the last 26 have been in healthcare. He has lived and worked overseas for 15 years including over six years in Paris and London.
Former President & CEO, Verb Surgical
Scott Huennekens was the former President & CEO at Verb Surgical. Mr. Huennekens served as the CEO of Volcano Corporation from April 2002 to February 2015. Prior to taking over the leadership of Volcano Therapeutics Inc, he served as CEO of Digirad Corporation. He has over 25 years of experience in the medical device, technology and diagnostics sectors, including over 15 as the Chief Executive Officer. He is a Certified Public Accountant and received an M.B.A. from the Harvard Business School and a B.S. in Business Administration from the University of Southern California.
Partner, Andera Partners
General Partner, New Enterprise Associates
Josh Makower has dedicated his career to the creation of medical technologies that improve quality of life for patients. He is the founder of ExploraMed Development, LLC, a medical device incubator based on the West Coast. He is also a general partner with New Enterprise Associates (NEA), where he leads investing activity in the medical device and health technology arena. He holds over 300 patents and patent applications for medical devices in the fields of orthopedics, ENT, cardiology, general surgery, drug delivery, women’s health, and urology. He earned an MBA from Columbia University, an MD from the New York University School of Medicine, an SB in mechanical engineering from MIT and is a Member of the College of Fellows of The American Institute for Medical and Biological Engineering.
President & CEO, CBSET, Inc.
Peter Markham is a well known and accomplished executive with 25 years of management and regulatory experience in the field of GLP contract research. Prior to joining CBSET, Mr. Markham served as General Manager of the Worcester/Southbridge division of Charles River Laboratories where he had P&L responsibility for a multi-disciplinary pre-clinical business unit which serviced the Toxicology, Pharmacology, Surgery, Metabolism, Pharmacokinetics, and Bioanalytical Chemistry markets.
Principal at the European VC, Seroba Life Sciences
Jennifer McMahon is a Principal at the European VC, Seroba Life Sciences, having joined the investment team as an Analyst in 2011. She is based in Seroba’s Dublin office and is involved in both medtech and biotech deal origination and investing. After graduating from University College Dublin with an honours degree in Pharmacology, Jennifer completed a master’s degree programme in Biotechnology and Business. She sits on the board of directors of Endotronix and is a board observer of Atlantic Therapeutics. She was previously on the board of directors of Biosensia, prior to it merging with Kypha Diagnostics in 2018. She is a Dublin-hub Ambassador of the Sandbox network, a global community for ‘exceptional innovators’. In 2019, Jennifer joined the Advisory Board for the European Healthcare Businesswomen’s Association. She guest-lectures on venture capital at University College Dublin, Trinity College Dublin and the Royal College of Surgeons, Ireland.
Vice President of New Business Development, Johnson & Johnson
As Vice President of Business Development and a member of the Medical Devices Group Operating Committee, Susan has responsibility for licensing, acquisitions and divestitures for the Medical Devices Group. Susan joined J&J as a college recruit in the Finance organization. During her tenure in the Corporation, she transitioned through a number of positions with increasing responsibility through six operating companies, primarily within Finance and Business Development. Susan has been involved in a number of significant transactions within Medical Devices.
Partner, Seroba Life Sciences
Daniel O’Mahony is a Partner at Seroba Life Sciences and brings a wealth of experience in product development, strategic planning, licensing, corporate venturing, intellectual property management and commercialisation. Dr O'Mahony currently sits on the board of Atlantic Therapeutics, MedLumics, Novate Medical and PQ Bypass. He previously sat on the boards of Apica Cardiovascular (acquired by Thoratec), Covagen (acquired by Cilag/Janssen Pharmaceutical Companies of the Johnson & Johnson Group), Stokes Bio (acquired by Life Technologies), Straatum (acquired by Lam Research Corporation).
Managing Partner, Sofinnova Partners
Antoine Papiernik is a Managing Partner at Sofinnova Partners, which he joined in 1997. Antoine has been an initial investor and active board member in public companies like Actelion, ProQR, NovusPharma (then sold to CTI), Movetis (then sold to Shire), Mainstay, Pixium Vision and Stentys, which went public respectively on the Zürich stock exchange, the NASDAQ, the Milan Nuovo Mercato, the Belgium Stock Exchange, the Dublin Stock Exchange and EuroNext Paris, in Cotherix (sold to Actelion), CoreValve (sold to Medtronic), Fovea (sold to Sanofi Aventis) and Ethical Oncology Science (EOS, sold to Clovis Oncology).
Managing Partner, Valiance
Mr. Pensaert is the founder and CEO/CIO of Valiance, bringing over 20 years’ experience in growth investing. He leads the Investment Committee for the Valiance funds and is responsible for all aspects of the funds’ investment process. Mr. Pensaert is a Director of several Valiance entities and funds, as well as a Director of Myoscience, MDxHealth, JenaValve, 4Tech and MyCartis. He holds a BA in Business Economics from the Economics University in Gent, Belgium, and a Masters in Banking & Finance from the University of Aix-Marseille.
Senior Investment Manager, High-Tech Gruenderfonds
Dr. Martin Pfister studied biopharmacology at the University of Greifswald and New York University, and earned a doctorate in immunology at the University of Leipzig. Prior to joining High-Tech Grunderfonds Management, Pfister served as Managing Director of the Saxony State Ministry of the Economy and Labour’s coordination office for biotechnology & pharmaceuticals.
Anne Portwich, PhD, has been with LSP since 2001. She is a Partner in LSP’s Amsterdam office. Her prime focus and responsibility within LSP is to invest in unlisted securities. Over the years, she has been responsible for investments in numerous portfolio companies of LSP. She also played an essential role in raising LSP Health Economics Fund 2 in 2017, the largest European fund dedicated to medical technology with a fund size of EUR 280 million.
VP, Discovery Advanced Technology, Edwards Lifesciences
Stan Rabinovich joined Edwards Lifesciences in 2004 when Edwards acquired Percutaneous Valve Technologies, Inc. (PVT) of which he was co-founder, Executive Vice President and COO. PVT has pioneered the development of transcatheter heart valves. Prior to PVT, Stan was Corporate Director of Business Development for Datascope Corp.
Partner, Earlybird Venture Capital
Thom Rasche has been a partner at Earlybird Venture since 2007 where he focuses on the healthcare technology sector. Mr. Rasche joined Earlybird Venture Capital GmbH & Co as a Venture Partner in 2003. Since he joined Earlybird, he has been responsible for the medical device portfolio and for making new investments in this area.
Managing Partner & Co-Founder, Fountain Healthcare Partners
Manus is a PhD chemist who worked in product development at GSK in the UK before moving over to a series of licensing and business development roles at Elan. He moved to the US in the early 2000’s and joined Aidan in the corporate VC group before returning to Ireland to establish Fountain. In addition to his investing role, Manus leads investor relations and fund raising activities for the Fund.
General Partner, Ysios Capital
Josep Sanfeliu focuses on medtech investments and on structuring transactions. Josep serves on the board of MedLumics, Dermalumics,CVRx , Corwave, Anaconda Biomed, Babyscripts and Xeltis. Josep has over 15 years of experience in law, corporate finance and business development in connection with entrepreneurs and with intellectual property related companies.
Partner, Mavie Technologies
Ari Silverman is a Partner at Mavie Technologies where he bridges Western Medical technology companies to access the Chinese market, capital and talent by providing investment advisory and consulting services for cross-border transactions. He has over 15 years global life sciences experience, including 11 years in China, and is now based in Europe. Prior to Mavie Technologies, Ari was a partner and leader in McKinsey’s China/Asia Healthcare Practice based in Shanghai, where he worked with leading multinational healthcare manufacturers to build their China and Asia businesses for growth and scale.
President & Managing Partner, Endeavour Vision
Damien Tappy with more than two decades of Entrepreneurship and Venture Capital experience has developed a solid experience in creating, building and exiting businesses in a number of sectors including Information Technologies, Telecom and Medical Technologies. On behalf of Endeavour, Damien currently serves on the Board of CeQur and was previously board member of Symetis (acquired by Boston Scientific), Chairman of Bitplane (acquired by Andor Technology), Chairman of GeneSystems (acquired by Pall Corp) and Director of Cirpack (acquired by Thomson).